Bringing clinical trial opportunities to community oncology
Clinical trials for oncology drugs in the community setting is an integral component of OPN’s comprehensive platform for cancer care. By coordinating access to these clinical trial opportunities, OPN is able to offer its patients the ability to participate in leading edge clinical research normally limited to a restricted population. By giving community oncology patients access to these trials, OPN will expand access to new and innovative therapies for many underserved communities, and ensure patients receive off-labeled treatments in an IRB-approved, safe and protected environment.
If you have any questions regarding the studies listed below, please contact Heather Lyon at 818.254.2526 or by email.
To view the full trial description please click on the NCT number for the particular trial.
| Diagnosis | Protocol Title | Patient Population | Key Inclusion | Key Exclusion | NCT Number |
|---|---|---|---|---|---|
| Brain | An Open-label Phase 1/2 Dose Finding, Safety and Efficacy Study of Oral NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Uncontrolled Brain Metastasis in Patients With Select Solid Tumors. | Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Uncontrolled Brain Metastasis | -Stable or decreasing steroids 5 days prior to consent -Progression within 90 day must be outside radiation field or provonsenten by Bx/resection -Seizures must be controlled for 14 days prior to ICF | - Various previous Tx requirements - XRT of CNS lesions within 14 days before first dose - History of known lepomeningeal involvement | NCT06047379 |
| Breast | ELACESTRANT in Women and Men with CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer: An Open-Label Multicenter Phase 2 Study (ELCIN)-STML-ELA-0322 | Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer | - Chemotherapy naïve - 1 or 2 prior homonal therapies and no prior CDK4/6 inhibitor in the metastatic setting | - Prior chemotherapy or CDK4/6 inhibitor in the metastatic setting | NCT05596409 |
| Breast | A Phase 1b/2, Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer (ELEVATE)-STML-ELA-0222 | Estrogen Receptor Positive, HER-2 Negative, Metastatic Breast Cancer previously treated with a CDK4/6 inhibitor | - Multi-arm umbrella study - Chemotherapy naïve and 1 or 2 prior hormonal therapies in the metastatic setting, one of which was in combination with CDK4/6 inhibitor (except for Arm D). PIK3CA mutation + required for Arm A. | - Prior chemotherapy in met. setting * Arm A: Prior Tx with alpelisib or PI3K inhibitor. Prior h/o T1DM or uncontrolled T2DM * Arm B: Prior Tx with everolimus * Arm C: Prior Tx with Abemaciclib * Arm D: Prior Tx with CDK4/6 inhibitor | NCT05563220 |
| Breast | A Phase 2 trial for neoadjuvant trastuzumab deruxtecan with or without anastrozole for HER2 low hormone receptor positive (HR+) breast cancer* | Low HER2, Hormone receptor positive (HR+) Breast Cancer | –Previously untreated operable invasive carcinoma. –No evidence of distant disease –HER2-low, HR+ | –Recurrent/metastatic breast cancer –Prior systemic therapy for invasive cancer | NCT04553770 |
| Breast | A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice (TPC) in Participants With Triple-Negative Breast Cancer (TNBC) Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response (pCR) at Surgery* | Triple-negative Breat cancer (TNBC) who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response at Surgery | –Centrally confirmed TNBC –No evidence of locoregional or distant relapse –Had neoadjuvant treatment based on the KEYNOTE-522 regimen | –Has a known germline breast cancer gene (BRCA) mutation and eligible for adjuvant therapy with olaparib –Has Grade >2 peripheral neuropathy | NCT06393374 |
| Breast | A Phase 3, Open-Label, Randomized Study to Assess the Efficacy and Safety of Extended Therapy With Camizestrant Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients With ER+/HER2- Early Breast Cancer* | ER+/HER2- early breast cancer who completed definitive locoregional therapy and standard adjuvant endocrine therapy | –Histologically confirmed ER+/HER2- –Completed definitive locoegional therapy –Completed 2-5 years of adjuvant endocrine therapy | –Inoperable locally advanced or metastatic breast cancer | NCT05774951 |
| Breast | An open-label, Phase 2 dose optimization and expansion study to evaluate the safety and efficacy of BB1701 in previously treated participants with Human Epidermal Growth Factor Receptor 2 (HER2)-positive or HER2-low unresectable or metastatic breast cancer* | Previously Treated Subjects with HER2-positive or HER2-low Unresectable or Metastatic Breast Cancer | –Metastatic or unresectable BC that is histologically confirmed HER2-positive or HER2-low –Must have previously received T-DXd | –Presence of brain or subdural metastases –Diagnosed with meningeal carcinomatosis | NCT06188559 |
| Colorectal | Phase 3 Randomized, Open-label, Active-controlled Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb for Treatment-naïve Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation* | Treatment-Naïve Subjects with Metastatic Colorectal Cancer with KRAS p.G12C Mutation | –Pathologically documented metastatic colrectal adenocarcinoma with KRAS p.G12C mutation –Central confirmation of KRAS p.G12C mutation –Measurable metastatic disease per RECIST v1.1 | –Active, untreated brain metastases –Leptomeningeal disease –Previous treatment with a KRAS p.G12C inhibitor | NCT06252649 |
| Colorectal | A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer* | First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer | –Histologically or cytologically confirmed adenocarcinoma of the left-sided colorectal cancer –Must have unresectable or metastatic disease –KRAS, NRAS, BRAF wild-type tumor | –History of interstitial lung disease (ILD)/pneumonitis/pulmonary fibrosis –Has a prior or concurrent second malignancy other than the disease under study | NCT06662786 |
| Hematologic | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients With Previously Untreated Chronic Lymphocytic Leukemia* | Patients With Previously Untreated Chronic Lymphocytic Leukemia | –Diagnosis of CLL/SLL | –Uncontrolled autoimmune hemolytic anemia or idiopathic thrombocytopenia purpura –Known bleeding disorders | NCT05963074 |
| Lung | A Phase 3, Open-label, Randomized, Active Controlled, Trial Evaluating Orally Administered BI 1810631 Compared with standard of Care as First-line Treatment in Patients with Unresectable, Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC) Harbouring HER2 Tyrosine Kinase Domain Mutations | Not previously treated Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC) Harbouring HER2 Tyrosine Kinase Domain Mutations | -Documented human epidermal growth factor receptor 2 (HER2) mutation in the tyrosine kinase domain per local lab -No previous treatment for locally advanced or metastatic disease -Eligible to receive platinum-based doublet and pembrolizumab -Archieve tissue availabe for central testing | -Tumors with targetable alterations with apporoved available therapy | NCT06151574 |
| Lung | Phase 3, Open-label study of HLX10 Plus Chemotherapy (Carboplatin-Etoposide) in Comparison with Atezolizumab Plus Chemotherapy in Previously Untreated Patients with Extensive-Etage SCLC-HLX10-005-SCLC301 | Newly diagnosed Extensive Stage Small Cell Lung Cancer | - No prior systemic therapy for ES-SCLC. - Patients who received chemoradiotherapy for previous limited stage SCLC must be treated and have a treatment-free interval of at least 6 months | -Symptomatic brain metastasis | NCT05468489 |
| Lung | A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation-DZ2022E0005 | Stage IIIb-IV Metastatic NSCLC with EGFR Exon 20 insertion mutation. | - Metastatic NSCLC with EGFR Exon 20 insertion mutation. - Newly diagnosed or have not received prior systemic treatment for locally advanced or metastatic NSCLC. | - Prior treatment for locally advanced or metastatic and NSCLC | NCT05668988 |
| Lung | An Open-label, Phase 2 Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (Uncommon EGFR or Exon 19 deletion Mutations Only) | Locally Advanced or Metastatic NSCLC (Uncommon EGFR or Exon 19 deletion Mutations Only) | - Biopsy proven Locally advanced/metastatic NSCLC with 1) COHORT 1-primary uncommon EGFR mutations and ≤ 1 prior line of chemotherapy or immunotherapy OR 2) COHORT 2-acquired uncommon EGFR mutations with disease progression on while on continuous treatment with EGFR TKI-additional lines of chemotherapy or immunotherapy may have been given | - COHORT 1 - any prior EGFR TKI therapy - COHORT 2- prior second-generation EGFR TKI (e.g. afatinib or dacomitinib) | NCT06010329 |
| Lung | An Open-label, Phase 2 Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (Uncommon EGFR or Exon 19 deletion Mutations Only) | Locally Advanced or Metastatic NSCLC harboring a non-resistant uncommon EGFR mutation | ≤ 1 prior line of chemotherapy | - Prior Tx with EGFR TKI | NCT05168566 |
| Lung | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination With Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination With Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (COPERNICUS) | Participants with epidermal growth factor receptor mutated (EGFRm) NSCLC | –Confirmed advanced or metastatic NSCLC that is not amenable to curative intent therapy –Epidermal growth factor resistance-mutation | –History of interstitial lung disease –Uncontrolled tumor related pain | NCT06667076 |
| Lung | A Phase 1b/2, Open-label, Randomized Study of Vudalimab in Combination With Chemotherapy or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced Non-small Cell Lung Cancer* | Previously Untreated Patients with nonsquamous non-small cell lung cancer | –Histologically confirmed, locally advanced (unresectable) or metastatic nonsquamous NSCLC –No prior systemic treatment for advanced/metastatic NSCLC | –Known active CNS metastases and/or carcinoma meningitis –Active known or suspected autoimmune disease | NCT06173505 |
| Lung | A Phase 3b, Randomized, Multicenter, Open-label Study to Assess the Efficacy of Durvalumab Plus Tremelimumab Versus Pembrolizumab in Combination With Platinum-Based Chemotherapy for FirstLine Treatment in Metastatic Non-Small Cell Lung Cancer Patients With Non-Squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS& | Previously Untreated Patients with Metastatic Non-Small Cell Lung Cancer with Non-Squamous Histology with Mutations in STK11, KEAP1 or KRAS | –Histologically or cytologically documented Stage IV non-squamous NSCLC –Must have tumors with STK11 or KEAP1 or KRAS mutations –No prior chemotherapy or systemic therapy for metastatic NSCLC | –Any evidence of acute or uncontrolled diseases or history of allogenic organ transplant –Mixed small cell lung cancer and NSCLC histology | NCT06008093 |
| Lung | A Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation* | Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation | –Histologically confirmed diagnosis of unresectable or metastatic NSCLC with KRAS G12C mutation | –Prior systemic treatment for locally advanced or metastatic NSCLC –Active brain metastases | NCT04613596 |
| Lung | A Randomized, Phase 3, Open-label Study to Evaluate Sigvotatug Vedotin Compared With Docetaxel in Adult Participants With Previously Treated Non-small Cell Lung Cancer* | Metastatic or unresectable non-small cell lung cancer | –Histologically or cytologically confirmed diagnosis of locally advanced, unresectable or metastatic Stage IV NSCLC –NSCLC with nonsquamous histology | –Life expectancy less than 3 months –Known allergies/hypersensitivity/intolerance to or contraindication of taxanes or docetaxel. | NCT06012435 |
| Lung | Phase 2 trial of LP-300 in combination with carboplatin and pemetrexed in never smoker patients with relapsed advanced primary adenocarcinoma of the lung after treatment with Tyrosine Kinase Inhibitors* | Never smoker patients with relapsed advanced primary adenocarcinoma of lung after tyrosine kinase treatment | –Confirmed histopathological diagnosis of inoperable advanced primary adenocarcinoma –Locally advanced inoperable or metastatic lung cancer –Must be never smokers | –Patients with small cell, squamous cell, large cell, undifferentiated, mesothelioma, or any form of mixed histopathological diagnosis –Metastatic adenocarcinoma arising from any primary site other than the lung | NCT05456256 |
| Lymphoma | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma* | Relapsed/Refractory Follicular or Marginal Zone Lymphoma | –Histologically confirmed grade 1-3a FL or MZL –Previously treated with 1 or more lines of systemic therapy including anti-CD20 agent –Need for systemic therapy for FL or MZL | –Transformation to aggressive lymphoma –Ongoing need for corticosteroid treatment –Clinically significant cardiovascular disease | NCT05100862 |
| MDS (Myelodysplastic Syndrome) | A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate-Risk Myelodysplastic Syndrome (MDS) in ErythropoiesisStimulating Agent (ESA)-Naive Participants Who Are Non-Transfusion Dependent (NTD)* | Myelodysplastic Syndrome (MDS) in Erythropoiesis-Stimulating Agent-Naïve Participants who are Transfusion Dependent | –Documented diagnosis of MDS –Not tranfusion dependent –Erythropoiesis-stimulating agent naïve | –Participants with secondary MDS –Known history of diagnosis of AML –History of cerebrovascular accident | NCT05949684 |
| Multiple Myeloma | A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing Mezigdomide (CC92480), Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM)* | Subjects with relapsed or refractory multiple myeloma (RRMM) who received 1-3 prior lines of therapy and prior lenalidomide exposure | –Documented diagnosis of MM and measurable disease –Received 1-3 prior lines of antimyeloma therapy | –Had progression during treatment or within 60 days of last dose –Prior treatment with mezigdomide or pomalidomide | NCT05519085 |
| Pancreatic | A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Trial of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Treatment-Naive Metastatic Pancreatic Ductal Adenocarcinoma* | Patients With Treatment-Naive Metastatic Pancreatic Ductal Adenocarcinoma | –Histologically or cytologically confirmed PDAC that is metastatic –No previous treatment for PDAC in the metastatic setting | –Previously treated for locally advanced, unresectable PDAC –History of brain or leptomeningeal metastases –Prior treatment with a CD73 antagonist or inhibitor | NCT06608927 |
| Solid Tumor | A Phase 1, Multicenter, Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of Intravenously Administered LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors* | Patients with relapsed or refractory lymphomas and solid tumors | –ECOG status 0-2 –For lymphoma, at least one bi-dimensionally measurable disease site –Adequate organ function at screening and C1D1 | –History or suspicion of CNS lymphoma or meningeal involvement or CNS metastases –Ongoing unstable cardiovascular function | NCT06132503 |
| Solid Tumor | A Phase 1 Study of SGN-B6A in Advanced Solid Tumors* | Subjects who have Solid Tumors | –Disease indication –Histologically or cytologically confirmed metastatic or unresectable solid malignancy of an included tumor type | –History of another malignancy within 3 years before first dose –Known active CNS metastases –Carcinomatous meningitis | NCT04389632 |
| Solid Tumor | A first-in human, open-label, dose-escalation trial with expansion cohorts to evaluate safety and antitumor activity of GEN1042 in subjects with malignant solid tumors * | Patients with metastatic or locally advanced solid tumors | –Non-CNS solid tumors that is metastatic or unresectable and for whom there is no available standard therapy –Normal or adeqaute liver, renal, cardiac and bone marrow function | –Active, known or suspected autoimmune disease –History of non-infectious pneumonitis that required steroids –History of greater than or equal to grade 3 allergic reactions to monoclonal antobody therapy | NCT04083599 |
| Solid Tumor | A Phase 1a dose escalation study of LP-184 in patients with advanced or metastatic solid tumors* | Patients with advanced solid tumors who have relapsed from or are refractory to standard therapy or for whom no standard therapy is available | –Histologically or cytologically documented advanced solid tumor that is relapsed from or is refractory to standard treatment –Resolved acute effects of any prior therapy | –Exposure to anti-cancer therapy within 2 weeks –History of retinopathy and/or macular degeneration –Received radiation within 4 weeks of C1D1 –Acute and severe bacterial, viral, or fungal infection | NCT05933265 |
| Solid Tumor | A Phase 1/2 study to evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors that have a KRAS G12C mutation* | Patients with advanced solid tumors that have a KRAS G12C mutation | –Histologically confirmed diagnosis of a solid tumor malignancy with KRAS G12C mutation –Unresectable or metastatic disease | –Hisotry of intestinal disease or major gastric surgery or inability to swallow oral medications –Other active cancer | NCT03785249 |
*CBSC Trial